Masayuki Munekane

Assistant Professor, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University*Profile is at the time of the award.

2025Inamori Research GrantsBiology & Life sciences

Research topics
Development of antibody drug conjugate labeled with radiolabeled halogen
Keyword
Summary
Antibody-drug conjugates (ADCs) have been attracting attention as biopharmaceuticals that enable cancer cell-specific treatment. However, there are many cases in which sufficient therapeutic effects have not been observed in clinical trials. In this study, we aim to develop ADCs in which DNA-targeting drugs labeled with therapeutic radionuclides are linked to antibodies via stimuli-responsive linkers, and to develop nuclear medicine treatments that achieve high therapeutic effects by achieving both "high accumulation in cancer tissues (cancer cells) by antibodies" and "transfer of radiolabeled compounds released in response to stimuli such as low pH and reducing conditions in cancer cells to the nucleus (DNA)."

Comment

Nuclear medicine therapy is a cancer treatment that utilizes the cytotoxic effects of radiation emitted from radionuclides. Its high therapeutic efficacy has been gaining attention, particularly in cases such as patients with metastatic prostate cancer who have achieved complete remission after receiving a compound bound to an alpha-emitting radionuclide. However, awareness of this treatment remains low, and we aim to develop drugs that will contribute to its widespread adoption.

Find other recipients

Biology & Life sciences